Sanofi stock edges lower as RBC starts coverage with EUR 80 target
Published on 09/10/2026 at 15:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi stock (ISIN FR0000127771) traded at EUR 74.13 on Euronext Paris on September 9, 2026, modestly below the prior close as investors reacted to fresh analyst coverage from RBC Capital setting an EUR 80.00 price target on the shares.
RBC initiates coverage with Sector Perform
According to The Globe and Mail on September 9, 2026, RBC Capital analyst Trung Huynh initiated coverage of Sanofi with a Hold rating and set a price target of EUR 80.00, framing the call around a balanced risk reward profile for the French pharma group.
As Investing.com was cited on September 9, 2026, RBC Capital started coverage with a Sector Perform recommendation, highlighting transition risks in Sanofi's portfolio and positioning the EUR 80.00 target around 7.9 percent above the latest Euronext Paris price of EUR 74.13 at that time.
Consensus targets point to further upside
Per data summarized by Zonebourse on September 9, 2026, the average price objective from 24 analysts for Sanofi stands at EUR 94.45, implying about 26.4 percent potential upside relative to the EUR 74.13 quote recorded on Euronext Paris that day.
As MarketScreener reported on September 10, 2026, HSBC reiterated its Buy rating on Sanofi and raised its price target from EUR 95.00 to EUR 100.00, while Oddo BHF maintained a Neutral stance but trimmed its target from EUR 85.00 to EUR 82.00, underscoring differing views on the stock's upside as the company navigates its strategy and pipeline.
Recent price performance and valuation context
Per the Euronext Paris snapshot relayed by Zonebourse on September 9, 2026, Sanofi shares closed at EUR 74.70 on September 8, 2026 and then traded at EUR 74.13 during the following session, marking a 0.76 percent decline on the day and leaving the stock down about 3.9 percent over the past five trading days and roughly 10.4 percent since the start of the year.
According to The Globe and Mail, Sanofi shares have traded in a one year range between EUR 71.25 and EUR 91.15, so the EUR 74.13 level on September 9, 2026 places the stock closer to the lower end of its 52 week corridor than to the peak, which helps explain why several analysts still see meaningful upside despite near term volatility.
Legal setback in India highlights risk backdrop
Beyond analyst debate, the risk backdrop for Sanofi also includes legal and regulatory issues. As Medical Dialogues reported on September 10, 2026, the Supreme Court of India dismissed Sanofi India Limited's petition seeking to quash criminal proceedings arising from a Central Bureau of Investigation complaint related to pharmaceutical supplies to the Bhabha Atomic Research Centre in Mysore.
According to the same Medical Dialogues report, Sanofi India clarified in its stock exchange filing that the Supreme Court ruling does not record any finding of guilt and does not impose penalties or operational restrictions at this stage, yet the continuation of the case adds an element of legal uncertainty that broader Sanofi investors will monitor alongside earnings and pipeline milestones.
Stock level on Euronext Paris
At the latest available Euronext Paris price snapshot referenced in the Zonebourse data for September 9, 2026, Sanofi stock changed hands at EUR 74.13 under the SAN ticker, representing the primary listing and serving as the reference level for comparing analyst targets that currently cluster between EUR 80.00 and EUR 100.00.
Sanofi stock key data
- Company: Sanofi S.A.
- ISIN: FR0000127771
- Ticker: SAN
- Trading venue: Euronext Paris
- Price (as of September 9, 2026, 14:52): 74.13 EUR
- Market capitalization: based on analyst consensus target of 94.45 EUR implying about 26.4 percent upside versus 74.13 EUR (as of September 9, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: CAC 40
